Search results for "INFECTIOUS"

showing 10 items of 2953 documents

Leishmaniasis among organ transplant recipients.

2008

Leishmaniasis is a rarely reported disease among transplant recipients; however, the number of published cases has quadrupled since the beginning of the 1990s. Most cases have been observed in patients living in countries of the Mediterranean basin. Leishmaniasis is most commonly associated with kidney transplantation (77%), and cases are also recorded among patients undergoing liver, heart, lung, pancreas, and bone marrow transplantation. Visceral leishmaniasis (VL) is the most frequently observed clinical presentation, followed by mucosal leishmaniasis and more rarely cutaneous leishmaniasis. Transplant recipients with VL develop the classic clinical form of the disease, which is a febril…

medicine.medical_specialtybusiness.industryMediterranean RegionIncidence (epidemiology)LeishmaniasisDiseaseOrgan Transplantationmedicine.diseaseOrgan transplantationTransplantationInfectious DiseasesVisceral leishmaniasisCutaneous leishmaniasisInternal medicineImmunologymedicineHumansLeishmaniasis VisceralbusinessLeishmaniasisKidney transplantationThe Lancet. Infectious diseases
researchProduct

Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease

2011

The aim of this study was to evaluate micafungin efficacy for treatment of invasive candidiasis/candidaemia in patients with cancer. Modified intent-to-treat populations were analysed from two trials: one, in adults and children with confirmed Candida infection, compared micafungin (adults 100 mg day(-1); children 2 mg kg(-1) day(-1)) with liposomal amphotericin B (L-AmB 3 mg kg(-1) day(-1)); and the other, in adults only, compared micafungin (100 or 150 mg day(-1)) with caspofungin (50 mg day(-1); 70 mg loading dose). Primary efficacy endpoint in both trials was treatment success, defined as both clinical and mycological response at end of therapy. In the micafungin/L-AmB trial, 183/489 pa…

medicine.medical_specialtybusiness.industryMicafunginDermatologyGeneral MedicineNeutropeniabacterial infections and mycosesmedicine.diseaseMalignancyLoading doselaw.inventionSurgeryClinical trialchemistry.chemical_compoundInfectious DiseaseschemistryRandomized controlled triallawInternal medicinemedicineCaspofunginAdverse effectbusinessmedicine.drugMycoses
researchProduct

Community acquired pneumonia in children: Outpatient treatment and prevention

2015

There have been significant changes in community acquired pneumonia (CAP) in children in the last decade. These changes are related to epidemiology and clinical presentation. Resistance to antibiotics is also a changing issue. These all have to be considered when treating Community acquired pneumonia (CAP). In this document, two of the main Spanish pediatric societies involved in the treatment of CAP in children, propose a consensus concerning therapeutic approach. These societies are the Spanish Society of Paediatric Infectious Diseases and the Spanish Society of Paediatric Chest Diseases. The Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP) has also been …

medicine.medical_specialtybusiness.industryNeumonía adquirida en la comunidadmedia_common.quotation_subjectAdvisory committeeResistenciasResistance (psychoanalysis)medicine.diseasePediatricsRJ1-570Paediatric infectious diseasesTherapeutic approachPresentationPrevenciónStreptococcus pneumoniaeCommunity-acquired pneumoniaManagement of Technology and InnovationEpidemiologyTratamientoMedicinebusinessIntensive care medicineNiñosmedia_commonAnales de Pediatría (English Edition)
researchProduct

Boceprevir in the treatment of chronic hepatitis C virus infection

2011

1Hepatology-Liver Transplantation Unit, Digestive Medicine Service, Hospital Universitari La Fe, and National Network Center for Hepatology and Gastroenterology Research, instituto de Salud Carlos iii, CiBeReHD Spain; 2CSiSP, Center for Public Health Research, Public Health Department, Generalitat Valenciana and Microbioloy Department/ institut Cavanilles, University of Valencia, Valencia, Spain; 3National Network Center for Biomedical Research in epidemiology and Public Health, instituto de Salud Carlos iii, CiBeReSP Spain

medicine.medical_specialtybusiness.industryPublic healthImmunologyTransplantationchemistry.chemical_compoundInfectious DiseaseschemistryChronic hepatitisVirologyFamily medicineBoceprevirEpidemiologymedicinebusinessVirus Adaptation and Treatment
researchProduct

Subclinical Infections with Boutonneuse Fever in Western Sicily

1985

medicine.medical_specialtybusiness.industryRickettsiaceae InfectionsBoutonneuse Fevermedicine.diseaseDermatologyBoutonneuse feverInfectious DiseasesHumansImmunology and AllergyMedicinebusinessSicilySubclinical infectionJournal of Infectious Diseases
researchProduct

Systemic therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN-based systematic review and meta-analysis.

2020

Background The SCORTEN score is a specific predictor of mortality for patients with Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). There is little evidence in support of the common immunomodulating therapies for SJS/TEN. Objectives To systematically assess the effectiveness of several therapies for SJS/TEN through the SCORTEN score. Methods Databases were searched for original studies on the use of SCORTEN. Six meta-analyses were carried out on patients with SJS/TEN who received supportive care only or in combination with immunomodulating drugs: corticosteroids, cyclosporine, etanercept, immunoglobulins or a combination of corticosteroids with immunoglobulins. A multivaria…

medicine.medical_specialtybusiness.industryStevens johnsonRetrospective cohort studyDermatologymedicine.diseaseToxic epidermal necrolysisEtanerceptstomatognathic diseases030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInfectious DiseasesAdrenal Cortex Hormones030220 oncology & carcinogenesisInternal medicineMeta-analysisStevens-Johnson SyndromeCyclosporineMedicineHumansbusinessmedicine.drugRetrospective StudiesJournal of the European Academy of Dermatology and Venereology : JEADVReferences
researchProduct

Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma

2011

Objective  The aim of this study was to evaluate the safety and efficacy profile of pegylated interferon α-2b (PEG-IFN α-2b) in combination with photochemotherapy (PUVA) in the treatment of cutaneous T-cell lymphoma (CTCL) in comparison with standard IFN α plus PUVA. Design  Retrospective cohort study over a period of 7 years. Patients and interventions  A total of 17 consecutive CTCL patients (stage IA–IV) were retrospectively analysed for toxicity and response rates associated with PEG-IFN α-2b (1.5 μg/kg weekly) plus PUVA (n = 9) or standard IFN α-2a (9 MIU 3×/week) plus PUVA (n = 8). Main outcome measures  Differences of response rates (complete/partial remission), progression-free surv…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentCutaneous T-cell lymphomaDermatologymedicine.diseaseDermatologyGastroenterologyDiscontinuationchemistry.chemical_compoundInfectious DiseaseschemistryPegylated interferonInternal medicinePUVA therapyToxicitymedicinebusinessProspective cohort studyAdverse effectPsoralenmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing

2020

Abstract Background Few data are reported in the literature about the outcome of patients with severe extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) infections treated with ceftolozane/tazobactam (C/T), in empiric or definitive therapy. Methods A multicenter retrospective study was performed in Italy (June 2016–June 2019). Successful clinical outcome was defined as complete resolution of clinical signs/symptoms related to ESBL-E infection and lack of microbiological evidence of infection. The primary end point was to identify predictors of clinical failure of C/T therapy. Results C/T treatment was documented in 153 patients: pneumonia was the most common diagnosis (n = 46…

medicine.medical_specialtyceftolozane/tazobactammedicine.medical_treatmentCRRTTazobactamEnterobacteralesEnterobacteraleInternal medicineCRRT; ESBL; Enterobacterales; ceftolozane/tazobactam; septic shockMajor ArticlemedicineClinical endpointRenal replacement therapybusiness.industrySeptic shockRetrospective cohort studyOdds ratiomedicine.diseaseCeftolozane/tazobactam; CRRT; Enterobacterales; ESBL; Septic shockAcademicSubjects/MED00290Infectious DiseasesOncologyESBLseptic shockCeftolozanebusinessEmpiric therapymedicine.drugOpen forum infectious diseases
researchProduct

Evaluation of the Burden of HPV-Related Hospitalizations as a Useful Tool to Increase Awareness: 2007–2017 Data from the Sicilian Hospital Discharge …

2020

In light of the implementation of human papillomavirus (HPV) prevention strategies, epidemiological studies in different geographical areas are required in order to assess the impact of HPV-related diseases. The purpose of the present study was to describe the burden of HPV-related hospitalizations in Sicily. A retrospective observational study estimated 43,531 hospitalizations attributable to HPV from 2007 to 2017. During the observed period, there was a decrease for all HPV-related conditions with a higher reduction, among neoplasms, for cervical cancer (annual percent change (APC) = &minus

medicine.medical_specialtycervical cancerImmunologyimpact evaluationcervical cancer screeninglcsh:MedicineCervical cancer screeningArticleburdenscreening effectiveness03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoveryCervical carcinomaEpidemiologyHospital dischargeScreening effectiveneMedicinePharmacology (medical)030212 general & internal medicineHPV vaccinePharmacologyCervical cancerHPV-related diseasevaccine effectivenessbusiness.industrylcsh:Rvirus diseasesRetrospective cohort studymedicine.diseaseVaccine introductionhospitalization rateAnnual Percent Changefemale genital diseases and pregnancy complicationsInfectious DiseasesItaly030220 oncology & carcinogenesisbusinessVaccines
researchProduct

Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm

2020

The “novel” coronavirus disease 2019 (abbreviated “COVID-19”) is the third coronavirus outbreak emerging during the past two decades. This infectious disease, sustained by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has been recently declared a global pandemic by the World Health Organization. Despite the concerning epidemiological burden, many people, including some policymakers, are underestimating this pandemic and are remaining enigmatically inactive against a human pathology which, for a combination of reasons, can be reasonably defined as a perfect storm (i.e., the “wrong virus” at the “wrong time”). These many paradigmatic aspects include SARS-CoV-2 structure and pe…

medicine.medical_specialtycoronavirusOutbreakOutbreakReview ArticleGeneral Medicine030204 cardiovascular system & hematologymedicine.disease_causeepidemics03 medical and health sciences0302 clinical medicineInfectious disease (medical specialty)PandemicEpidemiologyCase fatality ratemedicinecoronavirus disease 2019 (COVID-19)030212 general & internal medicineOutbreak; coronavirus; coronavirus disease 2019 (COVID-19); epidemicsIntensive care medicineViral loadHuman PathologyCoronavirusAnnals of Translational Medicine
researchProduct